MURA
Mural Oncology plc

808
Loading...
Loading...
News
all
press releases
Mural Oncology To Be Acquired By XOMA Royalty
The Mural board of directors said that they have determined the acquisition and cash offer by XOMA is in the best interest of all its shareholders.
Stocktwits·1mo ago
News Placeholder
More News
News Placeholder
Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives
The company will cut approximately 90% of its workforce as part of the strategic shift.
Stocktwits·6mo ago
News Placeholder
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell...
Globe Newswire·1y ago
News Placeholder
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H...
Globe Newswire·2y ago
News Placeholder
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Globe Newswire·2y ago
News Placeholder
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and...
Globe Newswire·2y ago
News Placeholder
Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference
DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Globe Newswire·2y ago
News Placeholder
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...
Globe Newswire·2y ago
News Placeholder
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful data Mural intends to nominate development...
Globe Newswire·2y ago

Latest MURA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.